MedGenesis Therapeutix Inc.
http://www.medgenesis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MedGenesis Therapeutix Inc.
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline
Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.
Straightforward Surgery Advances Drug Delivery To The Brain
Adopting an established endoscopic nasal grafting technique, researchers at Mass Eye and Ear have shown the ability to deliver a drug across the blood-brain barrier effectively and with reduced side effects. Their work could move rapidly into clinical testing in neurodegenerative diseases and could form the basis for delivering a wide range of existing drugs as well as new compounds whose development is predicated on use of the technique.
Pfizer Talks Potential Spinout, Suggests Tax-Inversion Play Still Possible
With 10 months of profit-and-loss data from its division into innovative and established product units, Pfizer will continue considering whether a spin-out into two separate companies offers shareholders the best value, CEO Read tells quarterly call. He also said tax-inversion remains a viable strategy for the pharma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule